Indiana Named Radiopharmaceutical Capital of the World

The Hoosier State just leveled up in a major way. The U.S. Patent and Trademark Office has officially named Indiana the Radiopharmaceutical Capital of the World. The new designation puts Indiana at the center of cutting-edge cancer care and precision medicine.

What Are Radiopharmaceuticals?

So what exactly are radiopharmaceuticals? They’re powerful medications that use radioactive ingredients, known as radioisotopes, to diagnose and treat a number of diseases, like hyperthyroidism, and even cancer.

Why Indiana Is Leading the Way

Anchored by the presence of major players like Novartis, POINT Biopharma, and Isotopia Molecular Imaging, Indiana is becoming a hub for the production of medical isotopes and targeted radiotherapies. -Biocrossroads

Get our free mobile app

Radiopharmaceuticals are high-tech, life-saving therapeutics, and Indiana is at the forefront. With top-notch research institutions, specialized labs and facilities, and a logistics network that can reach most of the U.S. in a day, thanks to Indiana's centralized location, the Hoosier State is uniquely built to lead this fast-growing industry.

Indiana is home to 15 nuclear medicine companies in various stages of growth and development, according to BioCrossroads. - Indiana Capital Chronical

Industry Titans Are Investing in Indiana

BioCrossroads, an organization focused on growing Indiana’s life sciences sector, led the charge to secure the trademarked title, and major players have taken notice. Companies like Eli Lilly, Novartis, and Bristol Myers Squibb, through their $4.1 billion acquisition of RayzeBio, are investing heavily right here in the Hoosier state.

Canva

Eli Lilly and Company continues to grow its radioligand therapy portfolio as part of its broader oncology strategy, building on its acquisition of POINT Biopharma and leveraging Indiana’s strengths in development and manufacturing. Novartis is expanding access to advanced treatments like Pluvicto as it deepens its U.S. radiopharmaceutical footprint. RayzeBio, now part of Bristol Myers Squibb following a $4.1 billion acquisition, recently celebrated the opening of its targeted radiopharmaceutical therapy facility in Indiana. The state is also home to a growing number of innovators including AZIsotopes, Oranomed, Curium, Telix Pharmaceuticals, and others, together reinforcing Indiana’s position as a national hub for next-generation precision medicine. - Central Indiana Corporate Parntership

Universities Fueling the Talent Pipeline

In addition to the pharmaceutical manufacturing across the state, Purdue University is launching the first-ever graduate program in radiopharmaceutical manufacturing in Indianapolis in the spring of 2026. Meanwhile, Indiana University School of Medicine continues to lead with top-ranked research, helping fuel a new generation of talent.

Indiana Tops the Nation in Life Sciences Exports

Indiana recently passed California as the #1 state for life sciences exports. We’re also leading the nation in pharmaceutical exports overall. Now, with this new designation, Indiana is officially on the map as a global hub for next-generation medical innovation.